Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine

Pharmaceutical Research

Volumn 32, Issue 4, 2015, Pages 1505-1515

  Soema, Peter C ^a,b,d   Rosendahl Huber, Sietske K ^c   Willems, Geert Jan ^a   Jiskoot, Wim ^b   Kersten, Gideon F A ^a,b   Amorij, Jean Pierre ^a  

^a Institute for Translational Vaccinology (Intravacc)   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Intravacc (Institute for Translational Vaccinology)   (Netherlands)

Author keywords

cross protective; cytotoxic T cells; influenza vaccine; peptide vaccine; virosomes

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; INFLUENZA T CELL PEPTIDE MI 58 66; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIROSOME; CPG ODN 1826; EPITOPE; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; IMMUNOLOGICAL ADJUVANT; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE FRAGMENT; VIROSOME VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; INFLUENZA; MEMBRANE FUSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; GENETICS; IMMUNOLOGY; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; INFLUENZA VACCINES; MICE, INBRED C57BL; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; VACCINES, VIROSOME; VIRAL MATRIX PROTEINS; VIROSOMES;

EID: 84925497926     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1556-3     Document Type: Article

References (29)

1. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature. 1997;389(6651):554.
2. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931-9.
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888-97.
4. Brown LE, Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol Cell Biol. 2009;87(4):300-8.
5. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013;19(10):1305-12.
6. Stanekova Z, Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J. 2010;7:351.
7. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol. 2008;82(24):12241-51.
8. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, et al. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum Immunol. 2010;71(5):468-74.
9. Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slutter B, et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release Off J Control Release Soc. 2012;161(2):363-76.
10. Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine. 2000;18(14):1327-33.
11. Amacker M, Engler O, Kammer AR, Vadrucci S, Oberholzer D, Cerny A, et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int Immunol. 2005;17(6):695-704.
12. Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine. 2011;29(8):1657-65.
13. de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, Frijlink HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2007;32(1):33-44.
14. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 1987;6(9):2651-9.
15. Soema PC, Willems G-J, van Twillert K, van de Wijdeven G, Boog CJ, Kersten GFA, et al. Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses. PLoS One. 2014;9(3):e92806.
16. Wiesel M, Oxenius A. From crucial to negligible: functional CD8(+) T-cell responses and their dependence on CD4(+) T-cell help. Eur J Immunol. 2012;42(5):1080-8.
17. Li CK, Rappuoli R, Xu XN. Correlates of protection against influenza infection in humans-on the path to a universal vaccine? Curr Opin Immunol. 2013;25(4):470-6.
18. van de Sandt CE, Kreijtz JH, de Mutsert G, Geelhoed-Mieras MM, Hillaire ML, Vogelzang-van Trierum SE, et al. Human cytotoxic T lymphocytes directed to seasonal influenza a viruses cross-react with the newly emerging H7N9 virus. J Virol. 2014;88(3):1684-93.
19. Kammer AR, Amacker M, Rasi S, Westerfeld N, Gremion C, Neuhaus D, et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine. 2007;25(41):7065-74.
20. Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol. 1999;117(3):496-503.
21. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 1987;236(4804):944-7.
22. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol CVI. 2006;13(9):981-90.
23. Foged C, Hansen J, Agger EM. License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2012;45(4):482-91.
24. Budimir N, Meijerhof T, Wilschut J, Huckriede A, de Haan A. The role of membrane fusion activity of a whole inactivated influenza virus vaccine in (re)activation of influenza-specific cytotoxic T lymphocytes. Vaccine. 2010;28(52):8280-7.
25. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, et al. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS One. 2012;7(1):e30898.
26. Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity. 2013;39(5):939-48.
27. Schotsaert M, Saelens X, Leroux-Roels G. Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines. 2012;11(8):949-62.
28. Valkenburg SA, Li OT, Mak PW, Mok CK, Nicholls JM, Guan Y, et al. IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection. Proc Natl Acad Sci U S A. 2014;111(15):5676-81.
29. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189-202.